Among its other big-selling drugs, Avastin (bevacizumab) grew 9% while Rituxan/MabThera (rituximab) added 4% despite increasing competition, and new idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) continued its impressive roll-out, with sales of CHF 563m in its first full year on the market.
ロシュのEsbriet (pirfenidone) の年間の売上高は563Mスイスフランですぞ〜
1スイスフランは118円くらいですな
ttp://www.pmlive.com/pharma_news/roche_shares_slip_as_profits_miss_expectations_917938?SQ_DESIGN_NAME=2&
Among its other big-selling drugs, Avastin (bevacizumab) grew 9% while Rituxan/MabThera (rituximab) added 4% despite increasing competition, and new idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) continued its impressive roll-out, with sales of CHF 563m in its first full year on the market.
中国の市場はでかい
今に見ておれ〜 ＞＜